Sector News

Will docs jump on new biosims? Survey shows they’ll need some nudging

August 17, 2015
Life sciences
Drugmakers are well aware of the biosimilars threatening to steal sales and market share from some of the world’s best-selling biologics.
 
Doctors, though? Not so much, a new report suggests.
 
Doctor platform and community QuantiaMD recently surveyed 300 primary care physicians and specialists to find out just how much healthcare providers knew about the drugs. 78% of those polled said they were familiar with the term “biosimilar,” but only 38% could name one under consideration for FDA approval that would be relevant to their patients, Medical Marketing & Media report.
 
To make matters worse, only 17% of the doctors Quantia deemed most likely to prescribe biologics–and, thus, the most likely to prescribe biosimilars in the future–said they were “very likely” to do so. 70% said they either weren’t sure or were “somewhat likely” to write a biosimilar script.
 
That’s a problem for the copycat pharmas looking to steal a piece of the pie from blockbusters like Amgen’s Neupogen, AbbVie’s Humira and Johnson & Johnson’s Remicade. Whether biosimilars pick up steam will largely depend on doctors–and on their likelihood to order them for patients.
 
Right now, only one biosimilar has FDA approval, and that’s Zarxio, a Novartis copy of Neupogen that won’t roll out until September, per court orders.
 
In the meantime, though, what can drugmakers do to get the word out to docs? “There’s a lot of opportunity for education,” Rachel Daricek, QuantiaMD’s senior director of client services, told MM&M. ” … They haven’t seen any efficacy and safety data or seen any communication from pharma or their organization–they don’t know what to think.”
 
By Carly Helfand
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”